Cancer vaccines based on dendritic cells loaded with tumor-associated antigens - PubMed (original) (raw)

Review

Cancer vaccines based on dendritic cells loaded with tumor-associated antigens

N Burdin et al. Cell Biol Toxicol. 2001.

Abstract

Dendritic cells (DCs) can be used as an antigen presentation platform for vaccination against cancer. In this approach, DCs are expanded in vitro from monocyte-derived progenitors, and subsequently loaded with well-characterized tumor-associated antigens (TAAs). TAAs can be incubated with DCs in various forms, including peptides, recombinant proteins, plasmid DNA, formulated RNA, or recombinant viruses. Advantages and limitations of DC-based cellular vaccines against cancers, as well as preliminary results of clinical studies already performed in humans, are discussed. Importantly, significant advances in our understanding of the biology of DCs can be used to support the design of new vaccines or adjuvants in order to elicit TH1 cellular immune responses.

PubMed Disclaimer

Similar articles

• Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
  Silva M, Silva Z, Marques G, Ferro T, Gonçalves M, Monteiro M, van Vliet SJ, Mohr E, Lino AC, Fernandes AR, Lima FA, van Kooyk Y, Matos T, Tadokoro CE, Videira PA. Silva M, et al. Oncotarget. 2016 Jul 5;7(27):41053-41066. doi: 10.18632/oncotarget.9419. Oncotarget. 2016. PMID: 27203391 Free PMC article.
• Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.
  Kavanagh B, Ko A, Venook A, Margolin K, Zeh H, Lotze M, Schillinger B, Liu W, Lu Y, Mitsky P, Schilling M, Bercovici N, Loudovaris M, Guillermo R, Lee SM, Bender J, Mills B, Fong L. Kavanagh B, et al. J Immunother. 2007 Oct;30(7):762-72. doi: 10.1097/CJI.0b013e318133451c. J Immunother. 2007. PMID: 17893568 Clinical Trial.
• Tumor lysate-loaded Bacterial Ghosts as a tool for optimized production of therapeutic dendritic cell-based cancer vaccines.
  Dobrovolskienė N, Pašukonienė V, Darinskas A, Kraśko JA, Žilionytė K, Mlynska A, Gudlevičienė Ž, Mišeikytė-Kaubrienė E, Schijns V, Lubitz W, Kudela P, Strioga M. Dobrovolskienė N, et al. Vaccine. 2018 Jul 5;36(29):4171-4180. doi: 10.1016/j.vaccine.2018.06.016. Epub 2018 Jun 9. Vaccine. 2018. PMID: 29895501
• Advances in dendritic cell-based vaccine of cancer.
  Zhang X, Gordon JR, Xiang J. Zhang X, et al. Cancer Biother Radiopharm. 2002 Dec;17(6):601-19. doi: 10.1089/108497802320970217. Cancer Biother Radiopharm. 2002. PMID: 12537664 Review.
• Genetically engineered dendritic cell-based cancer vaccines (review).
  Bubeník J. Bubeník J. Int J Oncol. 2001 Mar;18(3):475-8. Int J Oncol. 2001. PMID: 11179474 Review.

Cited by

• Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development.
  Tang L, Pan S, Wei X, Xu X, Wei Q. Tang L, et al. Mol Ther. 2023 Nov 1;31(11):3146-3162. doi: 10.1016/j.ymthe.2023.09.021. Epub 2023 Oct 5. Mol Ther. 2023. PMID: 37803832 Review.
• Advances in Molecular Imaging Strategies for In Vivo Tracking of Immune Cells.
  Lee HW, Gangadaran P, Kalimuthu S, Ahn BC. Lee HW, et al. Biomed Res Int. 2016;2016:1946585. doi: 10.1155/2016/1946585. Epub 2016 Sep 20. Biomed Res Int. 2016. PMID: 27725934 Free PMC article. Review.
• Using modified antigenic sequences to develop cancer vaccines: are we losing the focus?
  Valmori D, Ayyoub M. Valmori D, et al. PLoS Med. 2004 Nov;1(2):e26. doi: 10.1371/journal.pmed.0010026. Epub 2004 Nov 30. PLoS Med. 2004. PMID: 15578104 Free PMC article.
• Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
  Galea-Lauri J, Wells JW, Darling D, Harrison P, Farzaneh F. Galea-Lauri J, et al. Cancer Immunol Immunother. 2004 Nov;53(11):963-77. doi: 10.1007/s00262-004-0542-8. Epub 2004 May 14. Cancer Immunol Immunother. 2004. PMID: 15146294 Free PMC article.
• alpha-Tocopheryl succinate sensitizes established tumors to vaccination with nonmatured dendritic cells.
  Ramanathapuram LV, Kobie JJ, Bearss D, Payne CM, Trevor KT, Akporiaye ET. Ramanathapuram LV, et al. Cancer Immunol Immunother. 2004 Jul;53(7):580-8. doi: 10.1007/s00262-004-0499-7. Epub 2004 Feb 25. Cancer Immunol Immunother. 2004. PMID: 14991239 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations